Colonoscopy Detects Neoplasias Not Found by Sigmoidoscopy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

PORTLAND, Oregon-Two large studies of colonoscopy as a primary screening tool for colon cancer show that the procedure detects advanced proximal neoplasias that would not be found with sigmoidoscopy.

PORTLAND, Oregon—Two large studies of colonoscopy as a primary screening tool for colon cancer show that the procedure detects advanced proximal neoplasias that would not be found with sigmoidoscopy.

David A. Lieberman, MD, of Oregon Health Sciences University and Portland Veterans Affairs Medical Center, led a study of 3,121 asymptomatic patients at 13 Veterans Affairs centers who underwent colonoscopy. The examination found one or more neoplastic lesions in 37.5% of patients. Of the 1,765 patients with no polyps in the distal colon, 48 (2.7%) were found to have advanced proximal neoplasms.

Patients with adenomas of any size in the distal colon were more likely to have advanced proximal neoplasia than were patients with no distal adenomas (odds ratio for patients with small adenomas, 2.6; for patients with large adenomas, 3.4). However, 66 (52%) of the 128 patients with advanced proximal neoplasia had no distal adenomas. Sigmoidoscopy would have missed these abnormalities (N Engl J Med 343:162-168, 2000).

Few Serious Complications

Of the more than 3,000 colonoscopies performed, all by the study investigators, who were selected because of their extensive experience with colonoscopy, there were only 10 serious complications during or immediately after the procedure (0.3%). There were six cases of gastrointestinal bleeding requiring hospitalization and one case each of myocardial infarction, cerebrovascular accident, Fornier’s gangrene, and thrombophlebitis. There were no perforations and no deaths related to the procedure.

Dr. Lieberman reported that 73.3% of the cancers identified on screening had no nodal involvement or distal spread. “These data suggest that screening with colonoscopy in asymptomatic men can detect early and potentially curable advanced neoplasia,” he said.

In the second study, from Indiana University, 1,994 asymptomatic adults underwent colon-oscopy screening. Thomas F. Imperiale, MD, reported that those who had polyps in the distal colon were more likely to have advanced proximal neoplasia than those without distal polyps. However, 23 (46%) of 50 patients with advanced proximal neoplasia had no distal polyps, for a prevalence of 1.5% (23 of 1,564 persons with no distal polyps).

Time to ‘Go the Distance’

In an editorial, Daniel K. Podolsky, MD, of Massachusetts General Hospital, called for both government and private insurers to provide coverage for primary colon cancer screening with colonoscopy for all average-risk persons 50 years of age or older.

“Relying on flexible sigmoidoscopy is as clinically logical as performing mammography of one breast to screen women for breast cancer,” Dr. Podolsky said. “It is time to go the distance.”

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.